{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:06:00Z","timestamp":1790899560845,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0297-7","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:02:30Z","timestamp":1434672150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat"],"prefix":"10.1186","volume":"10","author":[{"given":"Tatiana","family":"Remenova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbajan","family":"Chadha-Boreham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,19]]},"reference":[{"key":"297_CR1","unstructured":"Actelion. Zavesca\u00ae (miglustat capsules) prescribing information. Available at: http:\/\/www.zavesca.com\/ . Accessed 30 April, 2015."},{"key":"297_CR2","unstructured":"Miglustat (Zavesca\u00ae) Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000435\/human_med_001171.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125 . Accessed 30 April, 2015."},{"key":"297_CR3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","volume":"27","author":"D Elstein","year":"2004","unstructured":"Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757\u201366.","journal-title":"J Inherit Metab Dis"},{"key":"297_CR4","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110:2296\u2013301.","journal-title":"Blood"},{"key":"297_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","volume":"28","author":"R Heitner","year":"2002","unstructured":"Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002;28:127\u201333.","journal-title":"Blood Cells Mol Dis"},{"key":"297_CR6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481\u20135.","journal-title":"Lancet"},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765\u201372.","journal-title":"Lancet Neurol"},{"key":"297_CR8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0883073809344222","volume":"25","author":"MC Patterson","year":"2010","unstructured":"Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol. 2010;25:300\u20135.","journal-title":"J Child Neurol"},{"key":"297_CR9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"99","author":"JE Wraith","year":"2010","unstructured":"Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010;99:351\u20137.","journal-title":"Mol Genet Metab"},{"key":"297_CR10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ymgme.2009.07.003","volume":"98","author":"M Pineda","year":"2009","unstructured":"Pineda M, Wraith JE, Mengel E, Sedel F, Hwu WL, Rohrbach M, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab. 2009;98:243\u20139.","journal-title":"Mol Genet Metab"},{"key":"297_CR11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","volume":"34","author":"N Belmatoug","year":"2011","unstructured":"Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34:991\u20131001.","journal-title":"J Inherit Metab Dis"},{"key":"297_CR12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18:770\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"297_CR13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0006-2952(99)00384-6","volume":"59","author":"U Andersson","year":"2000","unstructured":"Andersson U, Butters TD, Dwek RA, Platt FM. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol. 2000;59:821\u20139.","journal-title":"Biochem Pharmacol"},{"key":"297_CR14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10545-014-9725-4","volume":"37","author":"M Amiri","year":"2014","unstructured":"Amiri M, Naim HY. Long term differential consequences of miglustat therapy on intestinal disaccharidases. J Inherit Metab Dis. 2014;37:929\u201337.","journal-title":"J Inherit Metab Dis"},{"key":"297_CR15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10545-012-9523-9","volume":"35","author":"M Amiri","year":"2012","unstructured":"Amiri M, Naim HY. Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of alpha-glucosidases, but not beta-galactosidases. J Inherit Metab Dis. 2012;35:949\u201354.","journal-title":"J Inherit Metab Dis"},{"key":"297_CR16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0957-4166(99)00468-1","volume":"11","author":"TD Butters","year":"2000","unstructured":"Butters TD, van den Broek LAGM, Fleet GWJ, Krulle TM, Wormald MR, Dwek RA, et al. Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron Asymmetry. 2000;11:113\u201324.","journal-title":"Tetrahedron Asymmetry"},{"key":"297_CR17","volume-title":"Ullmann\u2019s Encyclopedia of Inustrial Chemistry","author":"S Schiweck","year":"2012","unstructured":"Schiweck S, Clarke M, Pollach G. Ullmann\u2019s Encyclopedia of Inustrial Chemistry. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2012."},{"key":"297_CR18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0755-4982(04)98639-3","volume":"33","author":"P Dechelotte","year":"2004","unstructured":"Dechelotte P. Type 1 Gaucher\u2019s disease in the adult. Nutritional management during initiation of treatment with miglustat. Presse Med. 2004;33:494\u20136.","journal-title":"Presse Med"},{"key":"297_CR19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26:513\u201326.","journal-title":"J Inherit Metab Dis"},{"key":"297_CR20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","volume":"27","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24\u00a0months of treatment. Clin Ther. 2005;27:1215\u201327.","journal-title":"Clin Ther"},{"key":"297_CR21","first-page":"703","volume":"91","author":"P Giraldo","year":"2006","unstructured":"Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, et al. Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher\u2019s disease. Haematologica. 2006;91:703\u20136.","journal-title":"Haematologica"},{"key":"297_CR22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","volume":"94","author":"P Giraldo","year":"2009","unstructured":"Giraldo P, Alfonso P, Atutxa K, Fernandez-Galan MA, Barez A, Franco R, et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009;94:1771\u20135.","journal-title":"Haematologica"},{"issue":"Suppl 3","key":"297_CR23","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1007\/s10545-010-9193-4","volume":"33","author":"H Champion","year":"2010","unstructured":"Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, et al. Dietary modifications in patients receiving miglustat. J Inherit Metab Dis. 2010;33 Suppl 3:S379\u201383.","journal-title":"J Inherit Metab Dis"},{"key":"297_CR24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00005176-199902000-00008","volume":"28","author":"WR Treem","year":"1999","unstructured":"Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999;28:137\u201342.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"297_CR25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MPG.0b013e3181a4c0df","volume":"49","author":"T Lucke","year":"2009","unstructured":"Lucke T, Keiser M, Illsinger S, Lentze MJ, Naim HY, Das AM. Congenital and putatively acquired forms of sucrase-isomaltase deficiency in infancy: effects of sacrosidase therapy. J Pediatr Gastroenterol Nutr. 2009;49:485\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"297_CR26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1056\/NEJM198705213162104","volume":"316","author":"HK Harms","year":"1987","unstructured":"Harms HK, Bertele-Harms RM, Bruer-Kleis D. Enzyme-substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase-isomaltase deficiency. N Engl J Med. 1987;316:1306\u20139.","journal-title":"N Engl J Med"},{"key":"297_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/gut.45.1.89","volume":"45","author":"JP Buts","year":"1999","unstructured":"Buts JP, De Keyser N, Marandi S, Hermans D, Sokal EM, Chae YH, et al. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut. 1999;45:89\u201396.","journal-title":"Gut"},{"key":"297_CR28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1203\/00006450-198602000-00020","volume":"20","author":"JP Buts","year":"1986","unstructured":"Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986;20:192\u20136.","journal-title":"Pediatr Res"},{"key":"297_CR29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12335","volume":"161","author":"M Arends","year":"2013","unstructured":"Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013;161:832\u201342.","journal-title":"Br J Haematol"},{"key":"297_CR30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920\u20134.","journal-title":"Scand J Gastroenterol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0297-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-015-0297-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0297-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T18:50:52Z","timestamp":1553626252000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/10\/1\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0297-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,19]]},"article-number":"81"}}